molecular mechanisms of cancer metastasis in lung cancer 肺癌之重点培训.pptVIP

;Harvesting Biomarkers for Early Risk Assessment ;Why Lung Cancer? Why Need Biomarker?;Lung Cancer with Early Metastasis;Lung Cancer Natural History and Personalized Therapy;Quality of Life and Lung Cancer Therapy;Biomarkers;Four Levels of Biomarkers;Lung Cancer in East Asia – A Unique Disease;;Lung Adenoca is not just one cancer - East and West are Different -;Phase II Trials of First-line EGFR-TKI Monotherapy in NSCLC; N mutR RR PFS OS Sutani et al. BJC 2006 27 38% 78% 9.4M 15.4M Inoue et al. JCO 2006 16 33% 75% 9.7M Asahina et al. BJC 2006 16 24% 75% 8.9M Yoshida JTO 2007 21 41% 90.5% 7.7M Sequist et al. JCO 2008 31 35% 58% 8.9M 17.5M Yang et al. JCO 2008 55 61% 69% 8.9M 24.0M ;PFS in EGFR mutation-positive and wild-type patients (IPASS);T790M: Primary Resistance to Gefitinib;Acquired Resistance in NTUH;Detect EGFR Mutation in Tumor and PB by DNA Mass;Genome-Wide Identification of Novel Marker for Cancer Metastasis;Lung Cancer Invasion Cell Line Model;IV Metastasis Assay in SCID Mice;Proteomics for Metastatic Markers;Microarray and Pathway Analysis;Risk Score= 0.47NF1+0.51HGF+0.52HMMR+0.52IRF4+ 0.55ZNF264+0.55ErbB3+0.59STAT2+0.59CPEB4+ 0.65RNF4+0.75DUSP6+0.92MMD+1.32DLG2-1.09ANXA5- 0.84LCK-0.77FRAP1-0.58STAT1;;Low risk;Gene Signature for Lung Adenocarcinoma;Interaction Networks of Independent Prognostic Gene Sets;Combination of Gene Expression and MicroRNA Signatures and Lung Cancer Outcome;Claudin-1 is Down-regulated in Lung Adenocarcinoma;Claudin-1 and Survival of Lung Adenocarcinoma;Claudin-1 Inhibits Cancer Cell Migration/Dissociation;Strategy Towards Personalized Therapy of Lung Cancer ;Conclusion;5-Gene Signature for NSCLC